**Beta Bionics Secures $114.4 Million in Series C Funding to Accelerate Innovation in Diabetes Management**
In a significant milestone for diabetes care, Beta Bionics has successfully raised $114.4 million in its Series C funding round. As a pioneering commercial-stage medical technology company, Beta Bionics is dedicated to enhancing the health and quality of life for individuals who require insulin—known as people with diabetes (PWDs). The company is celebrated for its groundbreaking iLet Bionic Pancreas, recognized as the first FDA-cleared autonomous insulin delivery device available on the market. By integrating advanced adaptive algorithms, the iLet simplifies diabetes management and has the potential to dramatically improve health outcomes for a diverse range of PWDs.
The newly acquired funds will be instrumental in furthering Beta Bionics' mission to innovate and expand its product offerings. Specifically, the funding will facilitate ongoing research and development efforts, enhance manufacturing capabilities, and broaden market reach. With an eye toward future expansions, Beta Bionics aims to increase accessibility to its revolutionary technology, ensuring that more patients can benefit from the advantages of autonomous insulin delivery.
“This funding is a testament to the confidence our investors have in our vision of transforming diabetes management,” said a spokesperson for Beta Bionics. “Our commitment is to empower individuals living with diabetes through advanced technology that makes managing their condition simpler and more effective.”
To learn more about Beta Bionics and their groundbreaking solutions, visit [www.betabionics.com](http://www.betabionics.com) and for safety information, please visit [www.betabionics.com/safety](http://www.betabionics.com/safety).
